Nature’s Biopharma Dealmakers has featured our mission to understand the mechanisms of drug toxicity, rescue promising assets with previous safety issues, and get them to clinic in record time.
“In drug development, there is a risk that drug safety is assumed, but toxicity issues can result in the death of a project, or even a company. Our goal is to think about safety in mechanistic terms—to understand the issues associated with existing compounds and re-engineer them to create safe, efficacious drugs. Essentially to turn around drugs that have failed,” said Jordan Lane, CSO and co-founder of Ignota Labs.
Our unique application of AI to solve toxicity issues in drug development unlocks new opportunities for assets that would otherwise be abandoned, driving new therapeutics towards the market.
Read more:
‘Turning failing drugs into hope for patients,’ can be read in full at Biopharma Dealmakers.
Published: 3 June 2025 by Nature.
